Table 1.
Distribution of clinical characteristics of all breast cancer patients included in the study and divided according to the treatment
| All (n = 1,097) | Untreated (n = 695) | Tam Treated (n = 402) | |
|---|---|---|---|
| Age (years), No. (%) | |||
| ≤50 | 212 (19.3) | 172 (24.8) | 40 (10.0) |
| >50 | 885 (80.7) | 523 (75.2) | 362 (90.0) |
| Tumor size (cm), No. (%) | |||
| 0–2 | 410 (37.8) | 261 (38.1) | 149 (37.2) |
| >2–5 | 583 (53.7) | 365 (53.3) | 218 (54.5) |
| >5 | 92 (8.5) | 59 (8.6) | 33 (8.3) |
| Missing | 12 | ||
| Nodes, No. (%) | |||
| Node negative | 791 (72.1) | 574 (82.6) | 217 (54.0) |
| Node positive | |||
| 1–3 | 173 (15.8) | 72 (10.4) | 101 (25.1) |
| >3 | 133 (12.1) | 49 (7.0) | 84 (20.9) |
| S phase, No. (%) | |||
| Low (0 to <6%) | 277 (30.8) | 175 (30.8) | 102 (30.7) |
| Intermediate (≥6 to ≤10%) | 261 (29.0) | 151 (26.6) | 110 (33.1) |
| High (>10%) | 362 (40.2) | 242 (42.6) | 120 (36.1) |
| Missing | 197 | ||
| Ploidy, No. (%) | |||
| Diploid | 361 (38.4) | 230 (39.2) | 131 (37.0) |
| Aneuploid | 580 (61.6) | 357 (60.8) | 223 (63.0) |
| Missing | 156 | ||
| ER (fmol/mg), No. (%) | |||
| Negative (<3) | 161 (14.7) | 143 (20.6) | 18 (4.5) |
| Positive (≥3) | 936 (85.3) | 552 (79.4) | 384 (95.5) |
| PR (fmol/mg), No. (%) | |||
| Negative (<5) | 421 (39.6) | 294 (44.0) | 127 (32.2) |
| Positive (≥5) | 642 (60.4) | 374 (56.0) | 268 (67.8) |
| Missing | 34 | ||
| Median follow-up time (mo) | 84 | 85 | 84 |